Grifols (GRFS) EPS (Diluted) Growth (1y) (2014 - 2020)
Grifols (GRFS) EPS (Diluted) Growth (1y) (2014 - 2020) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -0.91% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 284.27% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -130.72% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -92.04% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.26% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 64.94% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -640.40% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -108.14% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -69.50% |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 69.41% |
| Dec 31, 2019 | -7.63% |
| Mar 31, 2019 | -26.28% |
| Dec 31, 2018 | -9.12% |
| Jun 30, 2018 | 2.13% |
| Mar 31, 2018 | 6.55% |
| Dec 31, 2017 | 486.30% |
| Jun 30, 2017 | 25.73% |
| Mar 31, 2017 | -35.02% |
| Dec 31, 2016 | 5.13% |
| Sep 30, 2016 | 1.67% |
| Jun 30, 2016 | 38.26% |
| Mar 31, 2016 | 163.23% |
| Dec 31, 2015 | -75.60% |
| Sep 30, 2015 | -65.56% |
| Jun 30, 2015 | -52.64% |
| Mar 31, 2015 | -12.98% |
| Dec 31, 2014 | 24.17% |